Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Sep;108(3):487-493.
doi: 10.1002/cpt.1853. Epub 2020 May 12.

Interventional Pharmacoeconomics: A Novel Mechanism for Unlocking Value

Anthony V Serritella  1 , Garth W Strohbehn  1   2 , Daniel A Goldstein  2   3   4   5 , Allen S Lichter  2 , Mark J Ratain  1   2
Affiliations
Review

Interventional Pharmacoeconomics: A Novel Mechanism for Unlocking Value

Anthony V Serritella et al. Clin Pharmacol Ther. 2020 Sep.

Abstract

Cancer care's sustainability is challenged by drug expenditures. In the absence of systemic change, innovation is needed to curtail drug costs. Interventional pharmacoeconomics (IVPE) utilizes clinical research to identify safe, efficacious, cost-conscious dosing regimens to extract maximum value from expensive therapies. Strategies include de-escalation of dosage, treatment duration and administration frequency, and substitution with therapeutic alternatives. In this review, we discuss how IVPE strategies have been successfully used and could be implemented going forward.

PubMed Disclaimer

References

    1. Shih, Y.-C.T., Smieliauskas, F., Geynisman, D.M., Kelly, R.J. & Smith, T.J. Trends in the cost and use of targeted cancer therapies for the privately insured nonelderly: 2001 to 2011. J. Clin. Oncol. 33, 2190-2196 (2015).
    1. Hematology/Oncology (Cancer) Approvals & Safety Notifications <https://www.fda.gov/drugs/resources-information-approved-drugs/hematolog.... Accessed January 31, 2020.
    1. Lichter, A.S. From choosing wisely to using wisely: increasing the value of cancer care through clinical research. J. Clin. Oncol. 36, 1387-1388 (2018).
    1. Ratain, M.J. Redefining the primary objective of phase I oncology trials. Nat. Rev. Clin. Oncol. 11, 503-504 (2014).
    1. Ratain, M.J. & Lichter, A.S. Potential for value-based prescribing of oral oncology drugs. Ann. Oncol. 29, viii562 (2018).

MeSH terms

Substances

LinkOut - more resources